A Phase 4 interventional study of Hydroxychloroquine Sulfate in Corona Virus Infection, sponsored by University Hospital, Akershus. Status unknown at 1 site in Norway. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2020-06-05.
Sponsored by University Hospital, Akershus · Phase 4, Interventional, and Treatment
In the current proposal, the investigators aim to investigate the virological and clinical effects of chloroquine treatment in patients with established COVID-19 in need of hospital admission. Patients will be randomized in a 1:1 fashion to standard of care or standard of care with the addition of therapy with chloroquine.
Chloroquine is one of two therapeutics (in addition to remdesivir) that has demonstrated in vitro inhibitory effects on SARS-CoV-2 and the drug is immediately available from national pharmacies. No delay is accordingly expected in treatment initiation after study commencement. In light of the evidence supporting chloroquine as a promising therapeutic in patients with COVID-19, the expected impact of the current proposal is considerable both in the short- and long-term. If successful, treatment with chloroquine has the potential to be the first evidence based treatment for COVID-19. The drug is affordable and the risk of side effects is low, making it an attractive therapeutic in large proportions of the population on a global scale.
In the current proposal aims to investigate the virological and clinical effects of chloroquine treatment in patients with established SARS-CoV-2 in need of hospital admission. The investigators hypothesize that early treatment with chloroquine in patients with established COVID-19 is safe and will significantly improve prognosis and impact clinical outcomes. More specifically, the investigators hypothesize that early treatment with chloroquine will increase the virological clearance rate of SARS-CoV-2, and lead to more rapid resolve of clinical symptoms, decreased proportion of patients with clinical deterioration and a decreased admission rate to intensive care units and in-hospital mortality. Considering the immediate and worldwide health emergency associated with the SARS-CoV-2 outbreak and the current lack of evidence based medical interventions for this patient group, studies investigating such possible treatment modalities in COVID-19 are direly needed.
The study is a two-arm, open label, pragmatic randomized controlled trial (RCT) designed to assess the virological and clinical effect of chloroquine therapy in patients with established COVID-19. Pragmatic clinical trials are characterized by focus on informing decision-makers on optimal clinical medicine practice and an intent to streamline procedures and data collection in the trial. By utilizing resources already paid for by the hospitals (physicians and nurses in daily clinical practice), pragmatic clinical trials can include a larger number of patients at a short time duration and at a lower cost. Due to the immediate need for study commencement and the time frame of the current proposal, a pragmatic approach will enable swift initiation of randomization and treatment. Data will be extracted from the data warehouse at Akershus University Hospital for eligible patient identification (i.e. electronic surveillance) and for automatic data extraction to the study specific database. The study will not be able to procure an acceptable placebo treatment and the study will accordingly not be placebo-controlled.
All patients at Akershus University Hospital with suspicion of acute respiratory tract infections are examined with a nasopharyngeal swab, with subsequent microbiological examination, including SARS-CoV-2 specific RT-PCR. Participants will be recruited from the entirety of the inpatients at the participating hospitals. Electronic real-time surveillance of laboratory reports from the Department of Microbiology will be examined regularly, with maximum interval 24 hours, for SARS-CoV-2 positive subjects.
The study aims to include patients by a sequential adaptive approach, where analyses are planned after the inclusion of 51 patients, with subsequent analyses after 101, 151 and 202 completed patients. All patients included in each sequence will be used for the final analyses of the entire study. This approach will enable frequent assessment of all outcome measures.
Data will be collected from the hospital electronic record system, including electronic patient records, laboratory and medical imaging systems, and prescribing systems. The data warehouse at Akershus University Hospital will be utilized for automatic data extraction to the study specific database. All clinical variables will be registered in the study eCRF system, including clinical endpoints and quantitative virological results from serial oropharyngeal specimens.
6,686 studies on the registry are indexed under Infections; 807 are open to participants now.
This study's enrollment of 53 is below the median of 120 across 4,199 interventional studies indexed under Infections.
Browse Infections studies →University Hospital, Akershus is the lead sponsor of 123 studies on the registry; 28 are open to participants now.
Counted across the registry records on this site, refreshed daily.
Exclusion Criteria:
Chloroquine therapy in addition to standard of care
Drug: Hydroxychloroquine Sulfate
Standard of care
400 mg hydroxychloroquine sulphate (equalling 310 mg base) twice daily for seven days
Also known as: Plaquenil
Rate of decline in SARS-CoV-2 viral load
Viral load assessed by real time polymerase chain reaction in oropharyngeal samples
Time frame: Baseline (at randomization) and at 96 hours
Change in National Early Warning Score score
National Early Warning Score score determines the degree of illness of a patient. Scores range from 0-20, with a higher score representing further removal from normal physiology and a higher risk of morbidity and mortality.
Time frame: Baseline (at randomization) and at 96 hours
Admission to intensive care unit
Transfer from regular ward to intensive care unit during index admission
Time frame: At all times after randomization during index admission (between admission and discharge, approximately 21 days)
In-hospital mortality
All-cause mortality during index admission
Time frame: At all times after randomization during index admission (between admission and discharge, approximately 21 days)
Duration of hospital admission
Total days admitted to the hospital (difference between admission date and discharge date of index admission)
Time frame: During index admission (between admission and discharge, approximately 21 days)
Mortality at 30 and 90 days
All-cause mortality assessed at 30 and 90 days
Time frame: At follow-up 30 and 90 days
Clinical status
Percentage of subjects reporting each severity rating on a 7-point ordinal scale: 1. Death 2. Hospitalized, on invasive mechanical ventilation or extracorporeal membrane oxygenation 3. Hospitalized, on non-invasive ventilation or high flow oxygen devices 4. Hospitalized, requiring supplemental oxygen 5. Hospitalized, not requiring supplemental oxygen 6. Not hospitalized, but unable to resume normal activities 7. Not hospitalized, with resumption of normal activities
Time frame: 14 days after randomization
Change in C-reactive protein concentrations
Change in C-reactive protein concentrations from randomization to 96 hours after randomization
Time frame: Baseline (at randomization) and at 96 hours
Change in alanine aminotransferase concentrations
Change in alanine aminotransferase concentrations from randomization to 96 hours after randomization
Time frame: Baseline (at randomization) and at 96 hours
Change in aspartate aminotransferase concentrations
Change in aspartate aminotransferase concentrations from randomization to 96 hours after randomization
Time frame: Baseline (at randomization) and at 96 hours
Change in bilirubin concentrations
Change in bilirubin concentrations from randomization to 96 hours after randomization
Time frame: Baseline (at randomization) and at 96 hours
Change in estimated glomerular filtration rate
Change in estimated glomerular filtration rate from randomization to 96 hours after randomization
Time frame: Baseline (at randomization) and at 96 hours
Change in cardiac troponin concentrations
Change in cardiac troponin concentrations from randomization to 96 hours after randomization
Time frame: Baseline (at randomization) and at 96 hours
Change in natriuretic peptide concentrations
Change in natriuretic peptide concentrations from randomization to 96 hours after randomization
Time frame: Baseline (at randomization) and at 96 hours
This study is status unknown, as verified in Jun 2020. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
University Hospital, Akershus